Co-Authors
This is a "connection" page, showing publications co-authored by Paul Bunch and Ralph D'Agostino.
Connection Strength
0.485
-
Hughes RT, Lack CM, Sachs JR, Hiatt KD, Smith S, Steber CR, Aly FZ, D'Agostino RB, Bunch PM. Predicting Extranodal Extension with Preoperative Contrast-enhanced CT in Patients with Oropharyngeal Squamous Cell Carcinoma. Radiol Imaging Cancer. 2025 Mar; 7(2):e240127.
Score: 0.230
-
Hughes RT, Razavian NB, Smith S, D'Agostino RB, Bunch PM, Ponnatapura J, Royce TJ, Ververs JD, Nightingale CL, Weaver KE, Farris MK. Radiologist Involvement in Radiation Oncology Peer Review: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024 Dec 02; 7(12):e2452667.
Score: 0.057
-
Burcher KM, Bloomer CH, Gavrila E, Kalada JM, Chang MJ, Gebeyehu RR, Song AH, Khoury LM, Lycan TW, Kinney R, D'Agostino R, Bunch PM, Shukla K, Triozzi P, Furdui CM, Zhang W, Porosnicu M. Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer. Ther Adv Med Oncol. 2024; 16:17588359231217959.
Score: 0.053
-
Hughes RT, Gebeyehu RR, Kalada JM, Lycan TW, Frizzell BA, Kinney RD, D'Agostino RB, Bunch PM, Triozzi P, Zhang W, Furdui CM, Porosnicu M. Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer. Future Oncol. 2023 May 18.
Score: 0.051
-
Porosnicu M, O'Brien Cox A, Waltonen JD, Bunch PM, D'Agostino R, Lycan TW, Taylor R, Williams DW, Chen X, Shukla K, Kouri BE, Walker T, Kucera G, Patwa HS, Sullivan CA, Browne JD, Furdui CM. Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status. Front Oncol. 2022; 12:939118.
Score: 0.048
-
Burcher KM, Lantz JW, Gavrila E, Abreu A, Burcher JT, Faucheux AT, Xie A, Jackson C, Song AH, Hughes RT, Lycan T, Bunch PM, Furdui CM, Topaloglu U, D'Agostino RB, Zhang W, Porosnicu M. Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2021 Nov 16; 13(22).
Score: 0.046